Abstract
Introduction: ω-3 carboxylic acids (ω3 CA), also called ω3 free fatty acids (ω3 FFA), with the trade name Epanova™ is a new formulation of eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) approved for the treatment of severe hypertriglyceridemia. The FFA form of EPA and DHA is associated with higher bioavailability than other forms of ω3 fatty acids, potentially resulting in efficacy at lower doses and less dependence on meal relationship.
Areas covered: The efficacy and safety of ω3 CA from clinical trials as well as PK and PD data will be reviewed. The mechanism of action of ω3 fatty acids in the lowering of triglycerides (TG) will be discussed and comparison is made with ω3 ethyl ester compounds.
Expert opinion: ω3 CA are a unique form of ω3 fatty acids that appear safe and effective in lowering serum TG and offer the possibility of better patient compliance due to lower-dose efficacy and the ability to take with or without food. ω3 CA lowered TG by 26 and 31% for the 2 and 4 g/day doses, respectively, and Apo CIII was also lowered 11 and 14%, respectively, as well.
Acknowledgement
The author thanks Kevin C Maki, PhD for kindly reviewing the manuscript and making editorial suggestions.
Declaration of interest
EM Roth has received speakers bureau for AstraZeneca. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.